Fetal tracheal balloon occlusion to boost lung growth in severe congenital diaphragmatic hernia
Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion for Severe Left Congenital Diaphragmatic Hernia
This will try a fetoscopic tracheal balloon procedure to promote lung development in fetuses with severe left congenital diaphragmatic hernia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05962346 on ClinicalTrials.gov |
What this trial studies
Participants undergo a fetoscopic endoluminal tracheal occlusion (FETO) procedure in which a detachable balloon is placed into the fetal trachea using a fetoscope and microcatheter to block the airway and encourage lung growth. The procedure is offered to singleton pregnancies with isolated severe left CDH and an observed/expected lung-to-head ratio (O/E LHR) under 25%, typically performed between 27+0 and 29+6 weeks' gestation. Patients must have a normal fetal karyotype, meet psychosocial criteria including the ability to reside near Mayo Clinic Rochester with a support person, and attend required follow-up visits. Safety and changes in lung development and neonatal outcomes are monitored after the procedure.
Who should consider this trial
Good fit: Ideal candidates are singleton pregnancies with isolated severe left CDH, O/E LHR <25%, confirmed normal karyotype, and who can undergo FETO between 27+0 and 29+6 weeks and remain near Mayo Clinic Rochester with support.
Not a fit: Patients with mild CDH, non-isolated or bilateral defects, abnormal fetal karyotype, or those unable to meet the timing, residence, or support requirements are unlikely to receive benefit from this procedure.
Why it matters
Potential benefit: If successful, the procedure could increase fetal lung growth and improve the chance of survival and breathing after birth.
How similar studies have performed: Previous clinical series and trials of FETO have reported improved lung growth and higher survival in selected severe CDH cases, although outcomes vary and the approach carries procedural risks.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Singleton pregnancy * Normal fetal karyotype or microarray. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \> 26 weeks * Isolated severe left CDH with O/E LHR \< 25% ) * Gestation age at enrollment prior to 29 wks plus 6 days. * Pulmonary hypoplasia with ultrasound O/E LHR \< 25% (measured at 18 0/7 to 29 5/7 weeks) at the time of surgery. * Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound * Patient meets psychosocial criteria: able to reside within 30 minutes of Mayo Clinic, Rochester and able to comply with the travel for the follow-up requirements of the trial; patient has a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic * Patient is willing and able to give informed consent * Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT) Exclusion Criteria: * Multi-fetal pregnancy * History of natural rubber latex allergy * Preterm labor, cervix shortened (\<20 mm) at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor * Psychosocial ineligibility, precluding consent: inability to reside within 30 minutes of Mayo Clinic, Rochester and inability to comply with the travel for the follow-up requirements of the trial; patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic * Right sided CDH or bilateral CDH, isolated left sided with O/E LHR \>25% measured at 18 0/7 to 29 6/7 weeks) as determined by ultrasound * Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram that will significantly worsen prognosis. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring * Maternal contraindication to fetoscopic surgery * History of incompetent cervix with or without cerclage * Placental abnormalities (previa, abruption, accreta) known at time of enrollment * Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy * Maternal HIV, Hepatitis-B, Hepatitis-C status positive. * Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality that will make the procedure technically unfeasible * No safe or technically feasible fetoscopic approach to balloon placement * Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Where this trial is running
Rochester, Minnesota
- Mayo Clinic Minnesota — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Mauro Schenone, MD — Mayo Clinic
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.